President Donald Trump signed an executive order Saturday directing the Food and Drug Administration to speed its review of psychedelic drugs, including ibogaine, psilocybin, LSD, and MDMA, for treating severe mental health conditions, with a sharp focus on veterans battling PTSD, depression, and traumatic brain injury.
The signing, which took place in the Oval Office with conservative podcaster Joe Rogan and former Navy SEAL Marcus Luttrell looking on, marks the most aggressive federal step yet toward bringing psychedelic-assisted therapy out of overseas clinics and underground settings and into regulated American medicine.
Trump framed the move as a direct response to a mental health crisis that conventional treatments have failed to resolve. As NBC News reported, the order directs the administration to ease restrictions and spur research on using the drugs for medical purposes, including conditions like severe depression. The FDA next week will issue national priority vouchers for three psychedelics, a mechanism that can cut review times from several months to a period of weeks.
The executive order fulfills pledges made by both Trump and Health Secretary Robert F. Kennedy Jr. to open federal doors to psychedelic medicine. Trump told those gathered in the Oval Office:
"Today's order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life."
He added that the treatments are in advanced clinical trials and said, "If these turn out to be as good as people are saying, it's going to have a tremendous impact." Trump also described the order as a way to "dramatically accelerate" access to potential treatments.
Breitbart reported that Trump told attendees the administration would open a pathway for ibogaine to be included in the Right to Try Act, and the government committed an additional $50 million for ibogaine research. That figure matches a Texas law passed last year that already allocated $50 million for ibogaine research in that state, an effort co-founded by former Texas Governor Rick Perry through his group Americans for Ibogaine.
FDA Commissioner Marty Makary said the national priority vouchers would allow certain drugs to be approved quickly "if they are in line with our national priorities." The FDA is also taking steps to clear the way for the first-ever human trials of ibogaine in the United States, a substance derived from a shrub native to West Africa that has been used for generations in religious ceremonies by members of the Bwiti faith in Gabon and neighboring nations.
The most compelling case for the order comes from the men and women who have already tried these treatments, often by leaving the country to do so. U.S. veterans in recent years have reported benefiting from ibogaine after traveling to clinics in Mexico that administer it, sometimes at great personal expense and outside any regulatory framework.
Marcus Luttrell, the former Navy SEAL whose memoir about a deadly mission in Afghanistan became the basis for the film Lone Survivor, told Trump directly that ibogaine changed his trajectory.
"It absolutely changed my life for the better."
Luttrell added: "You're going to save a lot of lives through it." His presence in the Oval Office alongside Rogan gave the signing a distinctly personal dimension, two men with large public platforms vouching for something the federal government has spent decades refusing to touch.
The administration's willingness to act on promises rather than defer to bureaucratic inertia stands in contrast to the pattern seen across many federal agencies. Trump has shown a similar bias toward action in recent legal fights over mandatory detention policy, where courts have backed the administration's enforcement-first approach.
Rogan, who joined Trump in the Oval Office, described how the idea gained traction. He said he texted Trump information on ibogaine, and the president's response was immediate: "Sounds great. Do you want FDA approval? Let's do it." That exchange captures something about how this administration operates, less committee, more conviction.
The Washington Examiner reported that Veterans Affairs Secretary Doug Collins said the order opens new possibilities for veteran mental health care. The order specifically targets drugs already designated as breakthrough therapies by the FDA, meaning they have shown enough clinical promise to qualify for an expedited review track.
Ibogaine is not without serious concerns. The drug is known to cause irregular heart rhythms and has been linked to more than 30 deaths in the medical literature, according to the Multidisciplinary Association for Psychedelic Studies. The National Institutes of Health briefly funded research on ibogaine in the 1990s but discontinued the work due to its "cardiovascular toxicity." It remains a Schedule I controlled substance.
Frederick Barrett, director of the Johns Hopkins Center for Psychedelic and Consciousness Research, acknowledged the difficulty:
"It's been incredibly difficult to study ibogaine in the U.S. because of its known cardiotoxicity."
But Barrett also saw potential in the executive order. "If the executive order can pave the way for doing objective, scientific research with this compound, it would help us understand whether it is truly a better psychedelic therapy than others," he said. That's a measured endorsement, not a blank check, but a recognition that the federal government's decades-long refusal to allow research has left a knowledge gap that only proper trials can fill.
A small Stanford University study enrolled 30 veterans who received ibogaine in Mexico. The results contributed to growing interest in the drug's potential, though the study's size underscores how little rigorous data exists. The order from Trump aims to change that by removing the legal barriers that have kept American researchers on the sidelines while clinics in places like Cancun treat thousands.
The administration's broader willingness to challenge entrenched institutional resistance has played out across multiple fronts. Whether pressing emergency appeals at the Supreme Court or rewriting drug policy, the pattern is the same: act where predecessors stalled.
Tom Feegel of Beond Ibogaine, which operates a clinic in Cancun, offered a sober assessment of the order's near-term impact. His clinic treated 2,000 people with ibogaine last year, at a cost of between $15,000 and $20,000 per person. The company also gave free treatment to about 100 veterans.
Feegel noted the limits of what an executive order can accomplish overnight:
"There will be no insurance coverage, it will still be considered unapproved and non-covered care. But what it does mean is that ibogaine shifts from being fringe and underground to being federally acknowledged."
That shift matters. Two states, Oregon and Colorado, have already legalized psychedelic therapy with psilocybin. Texas committed $50 million to ibogaine research. Perry, the former governor who co-founded Americans for Ibogaine, appeared on Rogan's podcast twice in the past two years to make the case for reducing federal limits on the drug. The executive order now gives that state-level momentum a federal tailwind.
Ismail Lourido Ali, co-executive director of the Multidisciplinary Association for Psychedelic Studies, said the order could encourage other states to follow Texas's lead.
"The stigma around Schedule I drugs is significant. It feels like this would give pretty substantial cover for Republican governors and legislatures to step into the ring in terms of funding research programs at their universities."
The New York Post reported that the order also establishes FDA protocols for the safe therapeutic use of psychedelics and improves data sharing on related studies. Government-sanctioned treatments could begin as soon as this summer, pending authorization.
Dr. Mehmet Oz framed the stakes plainly: "This is an entire paradigm shift away from a one-day-a-pill model, which has failed so many."
Fox News reported that doctors and advocates emphasized broader access would still require completed trials, regulatory review, trained providers, and medical oversight. Jay Kopelman, a veterans' advocate, said the order "opens a pathway to research that will further open doors to expedited approval of this life-saving medicine as a treatment for our veterans, and society, who have suffered for decades from treatment-resistant PTSD, TBI and depression."
Juliana Mercer, another supporter, put it in personal terms: "I think about veterans I served with, people who have done years of therapy, cycled through medications, and are still carrying the weight of their service."
The administration has shown it is willing to follow through on promises across a wide range of policy areas, from enforcement actions against foreign elites to rewriting the rules on drug research. Whether the FDA bureaucracy moves as fast as the executive order demands will determine whether this moment becomes a turning point or another unfulfilled Washington announcement.
For decades, the federal government told veterans to take another pill, try another therapist, wait another year. Trump just told the FDA to move. The veterans who've already gone to Mexico for treatment didn't need a study to tell them what they experienced. Now the question is whether Washington can catch up to what those men and women already know.
